Get inside Wall Road with Road Insider Premium. Declare your 1-week free trial right here.
Firm announcement – No. 53 / 2022
Zealand Pharma Will increase its Share Capital as a Consequence of Train of Worker Warrants
Copenhagen, Denmark and Boston, MA, US November 17, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology firm centered on the invention and growth of revolutionary peptide-based medicines, has elevated its share capital by a nominal quantity of DKK 123,993 divided into 123,993 new shares with a nominal worth of DKK 1 every. The rise is a consequence of the train of warrants granted underneath a number of of Zealand Pharma’s worker warrant applications.
Worker warrant applications are a part of Zealand Pharma’s incentive scheme, and every warrant offers the proprietor the best to subscribe for one new Zealand Pharma share at a prespecified value, the train value, in particular predefined time durations earlier than expiration. For a extra detailed description of Zealand Pharma’s warrant applications, see the corporate’s Articles of Affiliation, which can be found on the web site: zealandpharma.com.
The train value was DKK 100.80 per share for 41,675 of the brand new shares, DKK 127.00 per share for 82,318 of the brand new shares. The full proceeds to Zealand from the capital enhance quantity to DKK 14,655,226.
The brand new shares give rights to dividend and different rights from the time of the warrant holder’s train discover. Every new share carries one vote at Zealand Pharma’s normal conferences. Zealand Pharma has just one class of shares.
The brand new shares will likely be listed on Nasdaq Copenhagen after registration of the capital enhance with the Danish Enterprise Authority. Following registration of the brand new shares, the share capital of Zealand Pharma will likely be nominal DKK 51,637,179 divided into 51,637,179 shares with a nominal worth of DKK 1 every.
The amendments to Zealand Pharma’s Articles of Affiliation entailed by the share capital enhance have been set out beneath. A full copy of the amended Articles of Affiliation might be discovered at https://www.zealandpharma.com and registered as we speak with the Danish Enterprise Authority.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology firm centered on the invention and growth of peptide-based medicines. Greater than 10 drug candidates invented by Zealand have superior into medical growth, of which two have reached the market and three candidates are in late-stage growth. The corporate has growth and partnerships with various blue-chip pharma corporations in addition to business partnerships for its marketed merchandise.
Zealand was based in 1998 and is headquartered in Copenhagen, Denmark, with a presence within the US that features Boston. For extra details about Zealand’s enterprise and actions, please go to zealandpharma.com.
The above info accommodates forward-looking statements that present Zealand Pharma’s expectations or forecasts of future occasions. Such forward-looking statements are topic to dangers, uncertainties and inaccurate assumptions, which can trigger precise outcomes to vary materially from expectations set forth herein and should trigger all or any of such forward-looking statements to be incorrect. If all or any of such forward-looking statements show to be incorrect, our precise outcomes might differ materially and adversely from these anticipated or implied by such statements. All such forward-looking statements communicate solely as of the date of this launch and are based mostly on info accessible to Zealand Pharma as of the date of this launch. Besides as required by regulation, the Firm assumes no obligation to replace these forward-looking statements publicly.
| Anna Krassowska, PhD
Vice President, Investor Relations & Company Communications
E-mail: [email protected]